2026-04-05T10:43:34Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1253532025-11-20T15:09:32Zcom_2072_1057col_2072_478916col_2072_478917

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region Castellsagué, Xavier Ault, Kevin A. Bosch José, Francesc Xavier, 1947- Brown, Darron Cuzick, Jack Ferris, Daron G. Joura, Elmar A. Garland, Suzanne M. Giuliano, Anna R. Hernández Avila, Mauricio Huh, Warner Iversen, Ole-Erik Kjaer, Susanne Krüger Luna, Joaquin Monsonego, Joseph Muñoz, Nubia Myers, Evan Paavonen, Jorma Pitisuttihum, Punnee Steben, Marc Wheeler, Cosette M. Perez, Gonzalo Saah, Alfred Luxembourg, Alain Sings, Heather L. Velicer, Christine Papil·lomavirus Càncer de coll uterí Papillomaviruses Cervix cancer Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (similar to 50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2018-10-16T12:58:40Z 2018-10-16T12:58:40Z 2016-12-01 2018-07-24T12:14:54Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1016/j.pvr.2016.03.002 Papillomavirus Research, 2016, vol. 2, p. 61-69 https://doi.org/10.1016/j.pvr.2016.03.002 cc by-nc-nd (c) Castellsagué et al., 2016 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Elsevier Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))